InnoGI Technologies

Executive Summary

InnoGI Technologies is a Netherlands-based contract research organization (CRO) that has carved a niche in gastrointestinal (GI) modeling with its proprietary TIM® Platform. This suite of in vitro and in silico models simulates the entire GI tract, enabling pharmaceutical and nutritional companies to assess digestion, bioavailability, ADME, and microbiome interactions with high accuracy. Founded in 2016 and headquartered in Wageningen, the company supports clients in R&D and regulatory submissions, reducing reliance on animal models and human trials. Its technology is particularly valuable for drug developers targeting the GI tract, as well as for the growing microbiome and nutritional supplement markets. While the CRO space is competitive, InnoGI’s specialized expertise and validated models position it as a trusted partner for companies seeking deep insights into product behavior in the GI environment.

Upcoming Catalysts (preview)

• Q3 2026Strategic Partnership with a Top-10 Pharma Company60% success
• Q4 2026Launch of Next-Generation TIM Platform with AI Integration50% success
• Q4 2026New Service Offering for Microbiome-Metabolite Profiling70% success